Dr. Ding Wang
Claim this profileHenry Ford Hospital
Expert in Cancer
Studies Non-Small Cell Lung Cancer
49 reported clinical trials
116 drugs studied
About Ding Wang
Education:
- Holds an MD (Doctor of Medicine).
- Earned a PhD (Doctor of Philosophy).
Experience:
- Serves as the Medical Director of the Clinical Trials Office at Henry Ford Health System.
- Principal Investigator for over 150 clinical trials.
- Manages a team of clinical research professionals and ensures compliance with regulatory standards.
- Provides administrative and financial oversight for approximately 170 clinical research projects.
- Facilitates staff certification in Good Clinical Practice and Human Subject's Protection.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Stage III
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Ding Wang is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Digital Tomosynthesis vs. Standard Mammography
for Breast Cancer Screening
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Recruiting2 awards Phase 34 criteria
More about Ding Wang
Clinical Trial Related5 years of experience running clinical trials · Led 49 trials as a Principal Investigator · 22 Active Clinical TrialsTreatments Ding Wang has experience with
- Nivolumab
- Pembrolizumab
- Cisplatin
- Carboplatin
- Gemcitabine Hydrochloride
- Docetaxel
Breakdown of trials Ding Wang has run
Cancer
Non-Small Cell Lung Cancer
Tumors
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ding Wang specialize in?
Ding Wang focuses on Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ding Wang currently recruiting for clinical trials?
Yes, Ding Wang is currently recruiting for 22 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Ding Wang has studied deeply?
Yes, Ding Wang has studied treatments such as Nivolumab, Pembrolizumab, Cisplatin.
What is the best way to schedule an appointment with Ding Wang?
Apply for one of the trials that Ding Wang is conducting.
What is the office address of Ding Wang?
The office of Ding Wang is located at: Henry Ford Hospital, Detroit, Michigan 48202 United States. This is the address for their practice at the Henry Ford Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.